<DOC>
	<DOCNO>NCT00512083</DOCNO>
	<brief_summary>The overall aim study assess efficacy safety AS1411 , range dos , combine cytarabine , treatment patient primary refractory relapse acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Phase II Study AS1411 Combined With Cytarabine Treat Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>primary refractory relapse AML confirm diagnosis AML ( de novo secondary ) define WHO classification ( Vardiman 2002 ) age least 18 year initial diagnosis acute promyelocytic leukemia define FrenchAmericanBritish criterion ( Bennett 1976 ) patient blast crisis stage chronic myeloid leukemia receive highdose cytarabine ( total cumulative dose &gt; 6g/m sq ) last 6 month interval &lt; 6 month first onset last complete remission current relapse primary refractory leukemia receive three previous induction cycle relapse patient receive three previous treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Leukemia , Myeloid + Acute Disease</keyword>
</DOC>